MINOVIA THERAPEUTICS LTD
General Data
Reg Number
514704485
Sector
Biomed
Established
2011
No. of Employees
28
Stage
R&D
Additional Funding
1
Description
Minovia developed a platform - Mitochondrial Augmentation Technology (MAT) - transplanting healthy and functional mitochondria and measuring mitochondrial health. Current clinical trials are in Pearson (Pediatric) and MDS (adults) under FDA and Israe
Technology
Mitochondrial Augmentation Therapy (MAT). The MAT repairs damaged mitochondrial DNA by using autologous stem cells, enriched with maternal blood-derived mitochondria.
Targeted Customers
Clinicians, Researchers, Patients with Pearson Syndrome, Kearns Sayre Syndrome and Leigh Syndrome.
Management personnel
Natalie Yivgi-Ohana - CEO & Co-Founder
Winning details
Route name
Winning year
R&D Fund
R&D Fund
2024
R&D Program second/third year request for Entitled Growth Corporate
R&D Program second/third year request for Entitled Growth Corporate
2023
Applied Research Consortia - Applied Research Fund
Applied Research Consortia - Applied Research Fund
2024
Increasing participation of Israeli industrial corporations in the European Horizon program
Increasing participation of Israeli industrial corporations in the European Horizon program
2024